Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Shares Outstanding (Weighted Average) (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $47.2 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 33.94% to $47.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $47.2 million, a 33.94% increase, with the full-year FY2025 number at $38.9 million, up 87.74% from a year prior.
  • Shares Outstanding (Weighted Average) reached $47.2 million in Q1 2026 per RAPP's latest filing, up from $38.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for RAPP hit a ceiling of $47.2 million in Q1 2026 and a floor of $1.4 million in Q2 2023.
  • A 4-year average of $22.3 million and a median of $27.8 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 2312.73% in 2024, then rose 8.82% in 2025.
  • Tracing RAPP's Shares Outstanding (Weighted Average) over 4 years: stood at $1.5 million in 2023, then surged by 1277.25% to $20.7 million in 2024, then skyrocketed by 87.74% to $38.9 million in 2025, then grew by 21.32% to $47.2 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for RAPP at $47.2 million in Q1 2026, $38.9 million in Q4 2025, and $37.9 million in Q3 2025.